Mitral Valve Replacement in a Patient with Porcelain Aorta after Previous Myocardial Revascularization

Ignazio Condello*, Giuseppe Speziale
GVM Care & Research, Department of Cardiovascular Surgery, Anthea Hospital, Bari, Italy
*Corresponding author: ignicondello@hotmail.it
Received July 12, 2019; Revised August 18, 2019; Accepted August 27, 2019

Abstract Redo cardiac surgery represents a clinical challenge due to a higher rate of perioperative morbidity and mortality. Mitral valve (MV) reoperations can particularly be demanding in patients with patent coronary grafts, previous aortic valve replacement, calcified aorta or complications following a previous operation. In this article we describe technique to manage systemic hyperkalemia in 68-year-old man who underwent bioprosthetic mitral valve replacement, already undergone coronary artery bypass grafting 13 years, come in our clinic to aggravated dyspnea caused by severe stenosis of the mitral valve. Because cross-clamping would have a high risk of stroke owing to severe calcification of the ascending aorta systemic hyperkalemia and continuous blood perfusion can guarantee adequate myocardial protection particularly in the case of patent grafts, decreasing potential lesions due to demanding clamp placing.

Keywords: calcified aorta, no-touch technique, systemic hyperkalemia, mitral valve replacement, cardiopulmonary bypass


1. Introduction

Aortic cross-clamping in patients with porcelain aorta is associated with high mortality and morbidity rates. In this case report, we show an alternative technique in a porcelain aorta patient with myocardial revascularization, without the aortic manipulation, use of hypothermia and ventricular fibrillation, through systemic hyperkalemia.

2. Report of the Case

2.1. Patient Characteristics

At the cardiac surgery division from Anthea hospital Gruppo Villa Maria, Bari, Italy; in June 2018, was admitted for elective cardiac surgery, a male patient of 68 years old, height 170(cm), with a weight of 75 (kg). With diagnosis of mitral valvular stenosis transvalvular mean gradient 8 mmHg, the patient was subjected to myocardial revascularization in May 2005 for critical stenosis of the anterior descending coronary artery, treated with a left mammary artery implant. The ejection fraction estimated at echocardiography with the Simpson biplane method was 35% in 2018, absence of aortic insufficiency, at echocardiographic examination, was found a calcific ascending and thoracic aortic wall, during X-Ray and CT scan before surgery (Figure 1, Figure 2) [1]. Have not been found hemodynamically significant carotid stenosis. The patient did not have diabetes mellitus, renal failure, NYHA class II. Preoperative blood count values without significant alterations (Hemoglobin 11.5 g/ dl, Creatinine 1.10 mg/dl). The patient was a candidate for mitral valve replacement surgery with a Euroscore II 2.5%, and underwent a Mini-Mental State Examination, before the procedure he reported an index of 28, an expression of cognitive normality [2].

Figure 1. Preoperative chest radiography showed a hyperdense aspect of the ascending aorta and aortic wall
2.2. Surgical technique

A median sternotomy was performed; the detachment of the adherent tissues has been done with a beating heart. During the exploration phase by the first operator of the ascending aorta tract, a calcified aorta in the ascending portion was highlighted, strategically it was decided not to isolate the left internal mammary artery. After heparin administration an arterial cannulation was performed, with a 22 Fr EOPA 3D medtronic cannula in the proximal section of the aortic arch, and a selective cannulation of the superior vena cava medtronic venous Pacifico cannula 18 Fr, and the inferior vena cava was medtronic venous cannula 32 Fr. Cardiopulmonary bypass was performed at 35°C nasopharyngeal temperature, using goal directed perfusion as a protocol, an delivery of oxygen was (DO$_2$/BSA mean 321 ml / min / m$^2$),[3,4] cardiac index of 2.5 l/min/m$^2$, and the pH management technique was alpha stat. The potassium level (mmol / L of Blood gas Test) was used as nadir for the management of asystole with hyperkalemia [5], the potassium level during the first Blood Gas Test was 4.9 mmol/l. Were administered bolus 35 meq of K$^+Cl^-$ in the extracorporeal circulation through, the same dosage used for myocardial protection (Calafiore et al.)[6,7]. The diastolic release of the heart with asystole was obtained immediately, the Blood Gas test reported 7.9 mmol/liter of potassium; serial B.G.T were performed every 10 min to maintain the level, with a slow infusion of 20 meq of K$^+Cl^-$ (2meq/ml). Four minutes after asystole, the surgery replacement procedure was started, with surgical access for the left conventional atriotomy, the aortic valve did not present insufficiency during the procedure, this allowed this to the surgeon to have a good surgical vision, the stenotic valve was replaced with the traditional technique, has been used the Medtronic Hancock™ II Model T510C biological valve prosthesis size 25 mm (Figure 3), CO2 was administered with a 2.5 l / min flow in the field during the procedure; for the prophylaxis of air embolism. Bispectral index (bis) monitor remained at the value of 38 no modification of anesthesia was necessary [8], during bolus administration of K$^+Cl^-$ and throughout the procedure. The asystole was maintained for 43 minutes (Figure 1), the replacement was 36 minutes, before the left atrium was closed, a endocavitary aspirator was inserted; at the same time the heating of the patient was started, and they were administered 10 units of insulin actrapid® to lower potassium levels with 30 ml of 33% glucose solution. The potassium level returned from 7.8 mmol / l to 5.3 mmol / l, the glycemia from 220 mg / dl to 170 mg / dl after 13 minutes [9]. Resumption sinus rhythm of 63 beats per minute that was guided with pace maker atrial, weaning was guided with transesophageal echocardiography in middle esophageal projection for air removal, using vent and Trendelenburg position, the removal of the air lasted 4 minutes, and subsequently weaning from the extracorporeal circulation occurred [10]. The overall duration of the cardiopulmonary bypass was 54 minutes [11,12,13]. The result was comparable to conventional mitral valve replacement intervention, with the use of cross-clamping and the administration of myocardial protection in terms of results, for myocardial ischemic markers TnT (ng/L), (1.8); and in the administration of blood products only one bag of RBC during I.C.U stay and in duration of mechanical ventilation 8 hours.

Figure 2. Computed-tomographic C scan with Porcelain aorta before the procedure

Figure 3. Computed-tomographic C scan with Mitral Valve Replacement after procedure
Absence of complications and neurological sequelae attributable to gaseous embolism, no significant variability was reported at the follow-up for 24, 48 hours at seven days and at 20 days at the Mini-Mental State Examination (average index 27), no marker of myocardial damage, no inotropic support was used and renal function remained preserved, creatinine (0.98 mg / dl).

3. Discussion

Although the outcomes of reoperative cardiac surgery have improved, reoperative mitral valve surgery still poses a higher risk of mortality and post-operative complications, such as stroke, prolonged ventilation, and reoperation for bleeding, than first-time mitral valve surgery. The present case had several risk factors for redo mitral valve replacement. First, there was a high risk of stroke due to the heavily calcified ascending aorta, which prohibited us from performing routine ascending aortic cannulation and Aortic Cross Clamp. Second, the patent bypass graft increased the risk of reoperation due to the possibility of injury during reentry and during exposure of the internal thoracic artery grafts, which should be clamped during cardiopulmonary arrest. Due to these concerns, clumpless surgery under systemic hyperkalemia was planned.

4. Conclusion

This technique of cardiac arrest with systemic hyperkalemia in Redo, should reduce the incidence of stroke risk reported in the literature on the MVR under fibrillary arrest, avoid the use of bodily hypothermia, and circulatory arrest [14]. In conclusion, a systemic hyperkalemia approach with a clumpless technique combined might be a viable option for patients who need valve surgery, have a porcelain ascending aorta, and are at risk of embolic stroke.

References


